We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Read MoreHide Full Article
Key Takeaways
IMVT stock has risen 12.4% over the past month on growing confidence in IMVT-1402 and its pipeline.
IMVT-1402 showed promising initial phase II efficacy data in difficult-to-treat RA patients at week 16.
Immunovant ended fiscal 2026 with more than $900M in cash, supporting upcoming clinical milestones.
Shares of Immunovant (IMVT - Free Report) have risen 12.4% over the past month against the industry’s 1.5% decline, reflecting growing investor confidence in the company's long-term prospects. The rally has been fueled by encouraging clinical data from its lead candidate, IMVT-1402, increasing confidence in its autoimmune disease pipeline and a strong financial position.
Image Source: Zacks Investment Research
Immunovant’s Progress With IMVT-1402
IMVT continues advancing its lead next-generation neonatal fragment crystallizable receptor (FcRn) inhibitor, IMVT-1402, across multiple autoimmune indications. Its development program includes potentially registrational studies in Graves’ disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease, as well as a proof-of-concept trial in cutaneous lupus erythematosus (CLE).
In mid-May, the company reported promising early data from the open-label portion of the ongoing phase II study evaluating IMVT-1402 in D2T RA patients who had failed multiple prior advanced therapies. The study demonstrated promising and clinically meaningful ACR response rates at week 16. The candidate also showed encouraging efficacy in a subgroup of patients previously treated with both JAK and anti-TNF inhibitors, boosting confidence in its blockbuster potential. Further updates from the study are expected in the second half of 2026.
Top-line data from potentially registrational clinical studies evaluating IMVT-1402 for the treatment of patients with GD and MG are anticipated in 2027.
Immunovant expects to report top-line data from the proof-of-concept study of IMVT-1402 in CLE in the second half of 2026.
These clearly defined development milestones and upcoming catalysts have strengthened investor sentiment.
IMVT’s Strong Cash Position Reduces Financing Risk
Immunovant ended fiscal 2026 with more than $900 million in cash and cash equivalents. The cash balance is expected to extend IMVT’s cash runway through the commercial launch of IMVT-1402 for GD.
Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 6.3% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $2.10. Over the same period, EPS estimates for 2027 have risen to $4.81 from $4.14. LQDA shares have gained 107.7% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 30 days, earnings per share estimates for Immunocore’s 2026 were unchanged at 6 cents for 2026 and 87 cents for 2027. IMCR shares have lost 17.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Key Takeaways
Shares of Immunovant (IMVT - Free Report) have risen 12.4% over the past month against the industry’s 1.5% decline, reflecting growing investor confidence in the company's long-term prospects. The rally has been fueled by encouraging clinical data from its lead candidate, IMVT-1402, increasing confidence in its autoimmune disease pipeline and a strong financial position.
Image Source: Zacks Investment Research
Immunovant’s Progress With IMVT-1402
IMVT continues advancing its lead next-generation neonatal fragment crystallizable receptor (FcRn) inhibitor, IMVT-1402, across multiple autoimmune indications. Its development program includes potentially registrational studies in Graves’ disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease, as well as a proof-of-concept trial in cutaneous lupus erythematosus (CLE).
In mid-May, the company reported promising early data from the open-label portion of the ongoing phase II study evaluating IMVT-1402 in D2T RA patients who had failed multiple prior advanced therapies. The study demonstrated promising and clinically meaningful ACR response rates at week 16. The candidate also showed encouraging efficacy in a subgroup of patients previously treated with both JAK and anti-TNF inhibitors, boosting confidence in its blockbuster potential. Further updates from the study are expected in the second half of 2026.
Top-line data from potentially registrational clinical studies evaluating IMVT-1402 for the treatment of patients with GD and MG are anticipated in 2027.
Immunovant expects to report top-line data from the proof-of-concept study of IMVT-1402 in CLE in the second half of 2026.
These clearly defined development milestones and upcoming catalysts have strengthened investor sentiment.
IMVT’s Strong Cash Position Reduces Financing Risk
Immunovant ended fiscal 2026 with more than $900 million in cash and cash equivalents. The cash balance is expected to extend IMVT’s cash runway through the commercial launch of IMVT-1402 for GD.
Immunovant, Inc. Price and Consensus
Immunovant, Inc. price-consensus-chart | Immunovant, Inc. Quote
IMVT’s Zacks Rank & Stocks to Consider
Immunovant currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) , Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 6.3% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $2.10. Over the same period, EPS estimates for 2027 have risen to $4.81 from $4.14. LQDA shares have gained 107.7% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 30 days, earnings per share estimates for Immunocore’s 2026 were unchanged at 6 cents for 2026 and 87 cents for 2027. IMCR shares have lost 17.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.